HPV vaccine continues to be safe and effective, and its benefits continue to outweigh its risks

References

• Harper DM. Currently approved prophylactic HPV vaccines. Expert Rev. Vaccines8(12), 1663–1679 (2009).
   PubMed Web of Science ®Google Scholar
• Harper DM. Gardasil needs a new consent form. Expert Rev. Vaccines8(12), 1613–1614 (2009).
   PubMed Web of Science ®Google Scholar
• The FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N. Engl. J. Med.356(19), 1915–1927 (2007).
   PubMed Web of Science ®Google Scholar
• Hildesheim A, Herrero R, Wacholder S et al. Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial. JAMA298, 743–753 (2007).
   PubMed Web of Science ®Google Scholar
• Olsson S-E, Kjaer SK, Sigurdsson K et al. Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection. Hum. Vaccines5(10), 696–704 (2009).
   PubMed Web of Science ®Google Scholar
• Harper DM. Current prophylactic HPV vaccines and gynecologic premalignancies. Curr. Opin. Obstet. Gynecol.21(6), 457–464 (2009).
   PubMed Web of Science ®Google Scholar
• Garland SM, Hernandez-Avila M, Wheeler CM et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N. Engl. J. Med.356(19), 1928–1943 (2007).
   PubMed Web of Science ®Google Scholar
• Paavonen J, Jenkins D, Bosch FX et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a Phase III double-blind, randomised controlled trial. Lancet369(9580), 2161–2170 (2007).
   PubMed Web of Science ®Google Scholar
• The FUTURE II Study Group. Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3 and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Lancet369, 1861–1868 (2007).
   PubMed Web of Science ®Google Scholar
• Paavonen J, Naud P, Salmeron J et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet374(9686), 301–314 (2009).
   PubMed Web of Science ®Google Scholar
• Munoz N, Kjaer SK, Sigurdsson K et al. Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women. J. Natl Cancer Inst.102(5), 325–339 (2010).
   PubMed Web of Science ®Google Scholar
• Garland SM, Steben M, Sings HL et al. Natural history of genital warts: analysis of the placebo arm of 2 randomized Phase III trials of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine. J. Infect. Dis.199(6), 805–814 (2009).
   PubMed Web of Science ®Google Scholar
• Hampl M, Sarajuuri H, Wentzensen N, Bender HG, Kueppers V. Effect of human papillomavirus vaccines on vulvar, vaginal, and anal intraepithelial lesions and vulvar cancer. Obstet. Gynecol.108(6), 1361–1368 (2006).
   PubMed Web of Science ®Google Scholar
• Monk BJ, Burger RA, Lin F, Parham G, Vasilev SA, Wilczynski SP. Prognostic significance of human papillomavirus DNA in vulvar carcinoma. Obstet. Gynecol.85(5 Pt 1), 709–715 (1995).
   PubMed Web of Science ®Google Scholar
• De Vuyst H, Clifford GM, Nascimento MC, Madeleine MM, Franceschi S. Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: a meta-analysis. Int. J. Cancer124(7), 1626–1636 (2009).
   PubMed Web of Science ®Google Scholar
• Dawson B, Trapp RG. Basic and Clinical Biostatistics. Mcgraw-Hill, NY, USA (2004).
   Google Scholar
• Stanley M. Prospects for new human papillomavirus vaccines. Curr. Opin. Infect. Dis.23(1), 70–75 (2010).
   PubMed Web of Science ®Google Scholar
• Einstein MH, Baron M, Levin MJ et al. Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18–45 years. Hum. Vaccin.5(10), 705–719 (2009).
   PubMed Web of Science ®Google Scholar
• Block SL, Brown DR, Chatterjee A et al. Clinical trial and post-licensure safety profile of a prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine. Pediatr. Infect. Dis. J.29(2), 95–101 (2010).
   PubMed Web of Science ®Google Scholar
• Garland SM, Ault KA, Gall SA et al. Pregnancy and infant outcomes in the clinical trials of a human papillomavirus type 6/11/16/18 vaccine: a combined analysis of five randomized controlled trials. Obstet. Gynecol.114(6), 1179–1188 (2009).
   PubMed Web of Science ®Google Scholar
• Dana A, Buchanan KM, Goss MA et al. Pregnancy outcomes from the pregnancy registry of a human papillomavirus type 6/11/16/18 vaccine. Obstet. Gynecol.114(6), 1170–1178 (2009).
   PubMed Web of Science ®Google Scholar
• Agorastos T, Chatzigeorgiou K, Brotherton JM, Garland SM. Safety of human papillomavirus (HPV) vaccines: a review of the international experience so far. Vaccine27(52), 7270–7281 (2009).
   PubMed Web of Science ®Google Scholar